An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Breast Cancer Content
Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023
In the latest edition of touchREVIEWS in Oncology & Haematology, we are pleased to present a collection of articles that delve into the latest research and advancements in the field. From innovative therapies and genetic treatments to analyses of digital patient education tools, each article contributes to our evolving understanding of complex medical conditions, offering […]
Quality and Reliability of Spanish-language YouTube Videos on Breast Cancer
touchREVIEWS in Oncology & Haematology. 2023;19(2):33-40
Breast cancer is the leading cause of cancer death in Hispanic women in the USA. According to the American Cancer Society, as many as one in nine Hispanic women will develop invasive breast cancer during their lifetime and one in 49 Hispanic women will die from invasive breast cancer.1 Female breast cancer is also the most […]
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, EMSO 2023
Significant advancements in breast cancer research emerged from EMSO this year. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) […]
Trastuzumab duocarmazine in HER2+ metastatic breast cancer – TULIP trial results: Philippe Aftimos, ESMO 2023
The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician’s choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023. Dr. Philippe Aftimos, the study investigator from the Institute Jules Bordet in Belgium, presented the results at the conference and then discussed them […]
New and emerging agents in HER2-negative metastatic breast cancer: Implications for current and future practice
Experts in the management of breast cancer discuss new and emerging agents for HER2-negative metastatic breast cancer.
- Discuss how novel treatments may be integrated into clinical practice for HER2-negative mBC, including optimal patient identification and treatment sequencing
- Identify considerations surrounding the use of ADCs and evaluate how safety management may support adherence in patients with HER2-negative mBC
- Evaluate the latest data for novel and emerging ADCs in managing HER2-negative mBC
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients
touchREVIEWS in Oncology & Haematology. 2023;19(1):12-15
Breast cancer is the most common cancer among women worldwide, and more than a fifth of those diagnosed will develop incurable metastatic disease.1 Molecular testing to investigate genetic and genomic variation is essential to identify the most effective treatment plans for patients. Treatment options available for patients with breast cancer are directed through the receptor status […]
Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the ASCO annual meeting. She highlights data from the NATALEE study (NCT03701334), which met its primary endpoint at interim analysis, thus showing clinically meaningful benefit for patients with early breast cancer. The abstract entitled ‘Ribociclib and […]
Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. These include the phase 3 SONIA trial (NCT03425838) assessing CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer, and the final overall survival […]